Shares of Novavax (NASDAQ: NVAX) have been extremely volatile as the market tries to value the company's COVID-19 vaccine. In January of last year, the company's stock was valued at $4 a share. The stock zoomed higher when COVID-19 hit, the tiny company introduced its vaccine candidate, and saw early success in clinical trials.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting